You searched for "MET"
USANZ Trainee Week 2024
It is our pleasure to report on our attendance at the Urological Society of Australia and New Zealand (USANZ) Trainee Week in Brisbane at the end of 2024. Firstly, we would like to thank The Urology Foundation, BSoT and BAUS...Children left waiting up to two years for NHS continence care, new data reveals
Children with bladder and bowel conditions are waiting months – and in some cases years – for specialist NHS support, as overstretched continence services struggle to meet rising demand, new Freedom of Information (FOI) data reveals. FOI responses from more...MPs urge government to end continence pad ‘rationing’ after trusts found limiting supplies
A group of MPs have called on the government to intervene over what they describe as the “rationing” of continence products across the NHS, warning that thousands of patients are being left without adequate support and may be costing the...Preparing for the FRCS (Urol) viva
Ping! You look down to your phone and you have just received an email saying, “Congratulations, you have now successfully completed The Joint Committee on Intercollegiate Examinations section 1 of the Fellowship of the Royal College of Surgeons (Urol) exam.”...Imaging of varicoceles
A varicocele is a collection of dilated, tortuous spermatic veins of the pampiniform venous plexus. It is seen in 10-15% of the general population and is associated with both primary and secondary infertility. A varicocele is the most common cause...Recent developments in bladder cancer – MIBC
This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...
